A Plant-Derived Antioxidant Supplement Prevents the Loss of Retinal Ganglion Cells in the Retinas of NMDA-Injured Mice.

Purpose: To investigate the effect of plant-derived antioxidant compounds, identified with primary culture screening, on retinal ganglion cell (RGC) survival in mice under excitotoxic conditions. Additionally, to determine the effect of these compounds on the involvement of calpain inactivation. Materials and
Methods: Plant-derived antioxidant compounds including hesperidin, crocetin, and Tamarindus indica were administrated orally to C57BL/6J mice. The levels of lipid oxidation and calpain activation were assessed with a TBARS assay and western blotting. RGC survival was evaluated with a TUNEL assay and RBPMS immunostaining after intravitreal injection of NMDA.
Results: Plant-derived antioxidant compounds significantly ameliorated the increase in the level of MDA in the retinas after NMDA injury. Cleaved α-fodrin fragments were detected in the NMDA-injured retinas, and these fragments were significantly lower in mice that received the plant-derived antioxidant compounds. The plant-derived antioxidants also ameliorated increases in TUNEL-positive cells and RGC death after NMDA injection.
Conclusion: These results indicate that oral administration of plant-derived antioxidant compounds such as hesperidin, crocetin, and Tamarindus indica suppressed RGC death. This oral supplementation decreased lipid oxidation and excessive calpain activation in NMDA-injured retinas. Thus, our newly developed antioxidant supplement has a potential role in neuroprotective treatment for retinal diseases, such as glaucoma.

Introduction

Glaucoma is an optic neuropathy that is a common cause of visual impairment and blindness worldwide.1 Glaucoma is characterized by the progressive death of retinal ganglion cell (RGC) axons and the irreversible loss of vision.2 It is well known that elevated intraocular pressure (IOP) is the most significant risk factor for glaucoma. However, in some patients the speed of progression does not depend on IOP, suggesting that IOP-independent factors also influence glaucoma progression.3,4 It was previously reported that oxidative stress-associated compounds increase in the eyes and bodily fluids, such as the peripheral blood, urine, and aqueous humor of human glaucoma patients.5–8 Studies of various retinal-injury animal models have shown that oxidative stress is associated with RGC death in mice,9–12 and that treatment to decrease oxidative stress prevents RGC death after optic nerve injury.13,14 These reports show that oxidative stress plays a significant role in RGC death, and suggest that antioxidant therapy may be a promising treatment approach.

Oxidative stress is an important factor not only in glaucoma, but also in other neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis.15 In the retina, oxidative stress is believed to be an important risk factor for age-related macular degeneration (ARMD) and diabetic retinopathy (DR).16–18 Therefore, inhibiting oxidative stress has potential as a neuroprotective treatment in all these diseases, not only glaucoma. Past studies have found that supplementation with antioxidants has neuroprotective effects. For example, a landmark study, the Age-Related Eye Disease Study (AREDS), showed that antioxidant supplements had a beneficial effect in these diseases and could slow progression.

Our previous work demonstrated that several plant-derived compounds enhanced cell viability in retinal primary cultures under oxidative stress. In particular, hesperidin, a plant-derived bioflavonoid, suppressed oxidative stress and excessive calpain activation, preventing RGC death after N-methyl-D-aspartate (NMDA) injury in vivo. In the current study, we investigate the neuroprotective effect of plant-derived compounds that we identified through retinal primary culture screening.19

Materials and Methods

Animals

Male, 8–12-week-old C57BL/6J mice (SLC Co., Shizuoka, Japan) were used in this study. The mice were treated according to the principles presented in the guidelines of the Declaration of Helsinki and its guiding principles in the care and use of animals. The Ethics Committee for Animal Experiments at Tohoku University Graduate School of Medicine approved all experimental procedures, in accord with the Association for Research in Vision and Ophthalmology (approval #2017-229).

NMDA-Induced Retinal Injury

NMDA injury in the animals was induced as described in previous publications.19,20 Briefly, a 15 mM solution of NMDA (Sigma-Aldrich, St. Louis, MO, USA) in phosphate-buffered saline (PBS) was injected intravitreally (2 µL/eye). Animals were excluded if they had lens injuries or vitreous hemorrhage. Three mice in total were excluded from the experiments due to lens injury or vitreous hemorrhage. Anesthesia was induced with 10% pentobarbital in PBS (0.77 mg/kg).

Oral Supplementation

In a previous study,19 we reported 12 candidate neuroprotective compounds. Based on these results, we developed a supplement containing three of these candidate compounds: hesperidin, crocetin, and Tamarindus indica. Low-dose and high-dose versions of the supplement were prepared, from Wakamoto Pharmaceutical Co., Ltd, with total concentrations of 16 mg/kg and 160 mg/kg, respectively, in sterilized PBS (the composition in Table 1). The mice received supplementation with either a vehicle control (PBS) or one of the supplements for one week orally via gavage. Intravitreal injection of NMDA was then performed, and three hours later, the mice received a final dose of the supplement.

Table 1

The Composition of the Oral Supplement. The Units are All in mg. PBS Was Used as Vehicle, and the Mice of Control Group Were Taken Same Volume of PBS

Structual Component	0.4 mg/ 200 µL	4 mg/ 200 µL
Hesperidin	0.02	0.2
Crocetin	0.004	0.04
Tamarindus indica	0.02	0.2
Reduced maltose starch syrup	0.272	2.72
Partly pregelatinized starch	0.08	0.8
Stearic acid calcium	0.004	0.04

2-Thiobarbituric Acid Reactive Substances (TBARS) Assay

To determine lipid peroxidation as an indirect marker of oxidative stress, we measured malondialdehyde (MDA) in retinas extracted from the mice 6 hours after the intravitreal injection of NMDA, and performed a TBARS assay, as described previously.19,21 In brief, a retinal homogenate containing 0.5 mM butylated hydroxytoluene was incubated with a reaction mixture (0.81% SDS, 0.36% thiobarbituric acid, and 9% acetic acid). After heating and centrifugation, the supernatant was collected and its fluorescence was measured at 530 nm excitation and 590 nm emission with a fluorescence microplate reader (SpectraMax Gemini; Molecular Devices LLC, Sunnyvale, CA). The results were normalized with protein concentration, which was measured with the bicinchoninic acid protein (BCA) assay kit (Thermo Fisher Scientific, MA, USA).

Immunoblotting

Retinal protein extraction, SDS-PAGE and an immunoblot analysis were performed as described previously.22 Briefly, membranes were incubated in a blocking buffer containing rabbit anti-α-fodrin antibody (Abcam 1:2000) at room temperature for 1 h. The membranes were then incubated with HRP-conjugated anti-rabbit IgG (dilution 1:5000; Sigma), immunoreactive bands were developed with ECL prime (GE Healthcare, Life Sciences) and the bands were examined with ChemiDoc XRS+ (Bio-rad). As an internal control, membranes were incubated with rabbit anti-β-actin antibody (dilution 1:1000; Sigma) at 4° C overnight. The density of the immunoreactive bands was then determined with a digital scanner and Image J software.

Cell Counting with a TUNEL Assay

Apoptotic cells were identified with TdT-mediated dUTP nick end-labeling (TUNEL) as previously described.23 Briefly, 24 hrs after NMDA injection, the retinas were fixed, cryoprotected, and mounted onto slides. After washes with PBS, the sections were incubated with TdT enzyme. Then, the sections were incubated with rhodamine-conjugated anti-digoxigenin antibody. Slides containing the sections were shielded with Vectashield mounting medium with DAPI (Vector Laboratories). Photomicrographs of whole retinal sections were taken with a microscope (BZ-9000; Keyence). In detail, we took pictures of four sections from each eye and chose one section that passed through the optic nerve while keeping the retinal structure. Cell counting of TUNEL-positive cells in the inner nuclear layer (INL) was then performed. The number of immunopositive cells was normalized and expressed as the average for each 1-mm length as our previous method.20

Immunohistochemistry and Cell Counting

To identify RGCs, we used an antibody-recognizing RNA-binding protein with multiple splicing (RBPMS), which is a member of the RNA recognition motif family of RNA-binding proteins and is known as a selective marker of retinal ganglion cells.24,25 Immunohistochemical analysis was performed as previously described.19 Cryosections were made and blocked with blocking buffer (10% donkey serum in Tw-PBS) at room temperature for 1 h. The sections were then incubated with a primary antibody against RBPMS (Abcam, 1:200) at 4° C overnight. The sections were washed with Tw-PBS and incubated with Alexa Fluor 488 conjugated goat anti-rabbit IgG antibody (Invitrogen, 1:500) in blocking buffer at room temperature for 1 h. The sections were mounted on Vectashield mounting media with DAPI (Vector Laboratories, Burlingame, CA) and photographs of whole retinal sections were taken with a microscope (BZ-9000; Keyence). Cell counting of RPBMS-positive RGCs in the ganglion cell layer (GCL) was performed in whole retinal sections. The number of immunopositive cells was normalized and expressed as the average for each 1-mm length.

Statistical Analysis

All statistical analyses used JMP Pro 12 software for Windows (SAS Institute Inc.). All continuous variables were expressed as means ± standard deviation. Comparisons used a one-way ANOVA followed by the Student’s t-test or Dunnett’s test, with Bonferroni correction for multiple comparisons. P < 0.05 was considered statistically significant (*).

Results

Oral Supplementation Attenuated NMDA-Induced Lipid Peroxidation in the Retina

To determine whether our newly developed antioxidant supplement could ameliorate NMDA-induced oxidative stress, we performed TBARS assays of retinas extracted from experimental and control mice that had undergone the intravitreal administration of NMDA after receiving a diet including or not including our oral supplement. The TBARS assay allowed us to quantify the amount of MDA in the retinas. We found that the NMDA-injured retinas that received the high- or low-dose supplemented diet showed a lower level of MDA than the controls (controls: 1.26 ± 0.26 nmol/mg protein, low-dose supplement: 0.02 ± 0.03 nmol/mg protein, and high-dose supplement: 0.26 ± 0.21 nmol/mg protein; Figure 1). Thus, oral supplementation attenuated NMDA-induced oxidative stress.

Figure 1

Oral supplementation reduced lipid peroxidation after NMDA injury. The amount of MDA in the retina was evaluated with a TBARS assay 6 hours after the intravitreal injection of NMDA without supplementation or with a low- or high-dose supplement (16 mg/kg, 160 mg/kg). The average amount of MDA was calculated and is shown per mg of retinal protein (each group: n = 6). Data represent mean ± SD. ***p < 0.001.

Oral Supplementation Inhibited Calpain Activation After NMDA Injury in the Retina

Previous studies have shown that RGC death after NMDA injury results from excess calpain activation and oxidative stress, and that the intravitreous injection of hesperidin can suppress these effects.19 To determine whether oral supplementation could also suppress excess calpain activation, we used an immunoblot analysis to measure the fragmentation of α-fodrin, an endogenous substrate of calpain, in the retinas of NMDA-injured mice that received a low- or high-dose supplement or a non-supplemented diet. We found that 6 hours after NMDA injection, the level of cleaved α-fodrin (both the 145 kDa and 150 kDa fragments) was not significantly lower in the animals that received the low-dose supplement than in those that received the non-supplemented diet, but was about 20% lower in the animals that received the high-dose supplement (Figure 2A, and B). These findings show that oral supplementation contributed to the suppression of calpain activation after NMDA injury in the mouse retinas.

Figure 2

Oral supplementation reduced the cleavage of α-fodrin in the retina after NMDA injury. (A) Immunoblot analysis of α-fodrin in retinas without supplementation or with a low- or high-dose supplement 6 hours after NMDA injury. Representative immunoreaction image with anti-α-fodrin showing intact α-fodrin (280 kDa) and calpain-cleaved fragmented α-fodrin (145 and 150 kDa). β-actin was used as an internal control. (B) The relative density of the cleaved-fodrin immunoreactive band. Relative density was based on the cleaved-fodrin immunoreactive band 6 hours after NMDA injection. Data represent mean ± SD (each group: n = 6). *p <0.05.

Oral Supplementation Prevented the Loss of RBPMS-Positive Cells After NMDA Treatment in the Retina

To determine whether oral supplementation prevented apoptosis after NMDA injury in the retina, we performed a TUNEL assay on retinal sections taken from NMDA-injured mice that received the supplemented diets. We found that 24 hours after NMDA injury, the number of TUNEL-positive cells in the GCL layer was higher in the non-supplemented diet group than the other groups (non-supplemented group: 46.2 ± 5.2 cells/mm, low-dose supplement group: 33.6 ± 4.2 cells/mm, high-dose supplement group: 26.1 ± 5.4 cells/mm). Thus, the increase in TUNEL-positive cells after NMDA injury was attenuated in animals that received the supplemented diet (Figure 3A and B).

Figure 3

Decrease in TUNEL-positive cells after NMDA injury and supplementation. (A) Representative overlay photographs of retinal sections in mice with or without supplementation 24 hrs after NMDA injection. Red: TUNEL assay; blue: DAPI nuclear staining. Scale bar: 100 µm. (B) Histograms showing the TUNEL-positive cell count in the GCL of mice (non-supplementation group: n = 7, other groups: n = 8). Data represent mean ± SD, **P < 0.01, ***P < 0.001.

To further evaluate the survival of the RGCs, we performed RBPMS immunostaining. The number of RBPMS-positive RGCs was lower in the non-supplemented diet group and low-dose supplement group than the high-dose supplement group (10.7 ± 3.4, 12.2 ± 2.3, and 15.6 ± 4.0 cells/mm, respectively) (Figure 4A and B). This finding suggests that oral supplementation prevented RGC death after NMDA-induced retinal injury.

Figure 4

Increase in RBPMS-positive cells after NMDA injury and supplementation. (A) Representative images of RBPMS-positive RGCs 24 hours after the intravitreal injection of NMDA without supplementation or with a low- or high-dose supplement. GCL, ganglion cell layer; INL, inner nuclear layer. Scale bar: 100 µm. (B) Histogram showing the average number of RBPMS-positive cells in each group. Data represent mean ± SD (PBS, n = 8; low-dose supplement, n = 6; high-dose supplement, n = 8). *p <0.05.

Discussion

In the present study, we show that NMDA-induced lipid peroxidation and the number of TUNEL-positive cells in the retina decreased in mice that received a low-dose or high-dose oral supplement containing three plant-derived compounds with a strong antioxidant effect: hesperidin, crocetin, and Tamarindus indica. Furthermore, animals that received a high dose of the supplement also showed an increase in the number of RBPMS-positive cells. These results suggest that our novel oral supplement was effective in suppressing cell death in the retina of mice under conditions of experimentally induced high oxidative stress.

We found that lowering lipid peroxide in retinal cells with our supplement was associated with a neuroprotective effect in these cells. This reinforces other recent studies of the role of oxidative stress in RGC damage, which have shown that oxidative stress-associated damage causes RGC death,26 and is associated with RGC death in mice that were subjected to IOP-dependent retinal injury,27 excitotoxicity-induced retinal injury,10 and axonal degeneration.11 Human trials have also suggested that oxidative stress plays a role in glaucoma pathogenesis. For example, relationships have been observed between the level of oxidative DNA damage, IOP increases, and the severity of visual field defects in glaucoma patients.28 Systemic levels of oxidative stress, represented by skin autofluorescence (SAF), have been shown to be associated with mean deviation in patients with open-angle glaucoma.29 Systemic oxidative stress is also associated with glaucomatous damage in relatively young male patients.30 These results suggest that antioxidants should have a neuroprotective effect. Indeed, in mice with ocular hypertension, Tempol, a multifunctional antioxidant, had anti-inflammatory effects in the retina and optic nerve.31 Additionally, coenzyme Q10 has been shown to inhibit oxidative stress and confer neuroprotection in DBA/2J mice.32 Human trials have shown an association between glaucoma risk and a low intake of green vegetables,33 and extract of Ginkgo biloba, a nitric oxide scavenger, has a neuroprotective effect in some glaucoma patients.34 Therefore, many previous reports suggest that antioxidants may have potential as a therapeutic treatment for glaucoma. Our current study also demonstrates that oral supplementation with antioxidants can reduce retinal lipid oxidation and prevent retinal apoptotic cell death, so we consider that our supplement may also have potential as a therapeutic drug in clinical practice.

In the present study, we found that a reduction in RBPMS-positive cells and excessive calpain activation were not suppressed by a low-dose antioxidant supplement, but were suppressed by a high-dose supplement. Thus, for RGCs, the neuroprotective effect of the high-dose supplement might have acted by suppressing the activation of calpain. Calpain is a member of the Ca2+-activated cysteine protease family, and calpain activation increases the level of intracellular calcium via the Ca2+-gated ion channels. Calpain is associated with fundamental cellular events, including cell motility, differentiation, proliferation, and apoptosis.35 Previous studies have demonstrated that the overactivation of calpain occurs in RGC death.36–40 Therefore, inhibiting calpain overactivation might contribute to protecting the RGCs. In the current study, a low dose of the supplement appeared to produce a greater antioxidant effect than a high dose, but only the high dose induced a protective effect in the RGCs. This finding suggests that antioxidant activity is not the main neuroprotective mechanism. One possibility is that inflammation and endoplasmic reticulum (ER) stress may be involved. In our past study, we found that anti-inflammation and ER-stress blockade had a synergistic neuroprotective effect against NMDA injury in mice.20 Hesperidin suppressed the expression of inflammatory cytokines, such as TNFα, IL-1b, and IL-6, and MCP-1 after NMDA-induced excitotoxicity in the retinas of mice.20 Crocetin also suppressed ER-stress related proteins and prevented retinal cell damage.41 These studies suggest that our antioxidant supplement may also have a neuroprotective effect that acts via anti-neuroinflammatory and anti-ER stress signaling. In addition, recent studies have demonstrated that NMDA-induced injury is associated with nitrosative stress42 and that hesperidin can ameliorate aluminum-induced neurotoxicity by suppressing nitrosative stress.43 This neuroprotective mechanism may also have contributed to the effects we observed with our supplement treatment. Moreover, hesperidin shows an affinity for the NMDA receptor and prevents pentylenetetrazole-induced convulsions.44 Citrus aurantium extracts, including hesperidin, reduce glutamate binding with NMDA receptors.45 These findings suggest that hesperidin acts as an antagonist to the NMDA receptors and directly blocks the downstream signal. These neuroprotective mechanisms may also have contributed to RGC protection in our model.

Past studies have shown that the number of RGCs and amacrine cells declines in the ganglion cell layer after NMDA injury.46 Here, we chose to examine the effects of oral supplementation with three compounds (hesperidin, crocetin, and Tamarindus indica) that have been found to improve cell viability in retinal cells in vitro.19 Each of these compounds has been reported to have distinct pharmacological activities. First, hesperidin acts as an antioxidant,47 and has been shown to lower intracellular calcium (II) and reduce ROS level.48 Our previous work also showed that intravitreal injection of hesperidin attenuated lipid peroxidation after NMDA injury.19 Second, crocetin has been shown to possess the pharmacological action of countering oxidative stress by directly scavenging ROS,49 and can suppress atherosclerosis.50 Finally, Tamarindus indica has also been reported to have antioxidant potential, and to enhance antioxidant enzyme activities in HepG2 cells.51 Thus, past studies suggest that each compound acts as an antioxidant via different pathways. In the current study, we only investigated the effect of supplementation against oxidative stress by measuring MDA, and obtained results that we have previously shown for hesperidin alone.19 Determining if the three compounds in our new supplement have a synergistic neuroprotective effect will require further experiments.

In conclusion, the results of this study indicate that our newly developed oral supplement can prevent the death of retinal cells, including the RGCs, after the induction of excitotoxicity with NMDA in mice. We obtained evidence that the mechanism of this protective effect involves the suppression of ROS generation and the inhibition of calpain activation. Excitotoxic damage is believed to be one of the causes of glaucomatous neuropathy. In fact, elevated glutamate levels have been found in the vitreous body of eyes with glaucoma in humans and monkeys.52 Moreover, glutamate metabolism is involved with several ocular pathologies, such as diabetic retinopathy.53 Recently, we performed a clinical study that revealed that an antioxidant supplement including hesperidin, crocetin, and Tamarindus indica improved antioxidant levels in the blood of glaucoma patients with high oxidative stress.54 Therefore, dietary supplementation with plant containing hesperidin, crocetin, or Tamarindus indica has potential as a new therapeutic approach to protect against retinal damage associated with excitotoxic injury in diseases such as glaucoma and diabetic retinopathy.